UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 442

Sortiert nach

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

Annals of oncology, 2013-03, Vol.24 (3), p.577-585

2013

Link zum Volltext

Verfügbarkeit prüfen

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Link zum Volltext

Verfügbarkeit prüfen

Scorpion sting envenomation outbreak in Mexico. Strategies for prevention and control

Toxicon (Oxford), 2024-01, Vol.237, p.107549-107549, Article 107549

2024

Link zum Volltext

Verfügbarkeit prüfen

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

Oncogene, 2011-04, Vol.30 (15), p.1744-1752

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-10, Vol.24 (10), p.2601-2606

2013

Link zum Volltext

Verfügbarkeit prüfen

Treatment Receipt and Outcomes among Lung Cancer Patients with Depression

Clinical oncology (Royal College of Radiologists (Great Britain)), 2014-01, Vol.26 (1), p.25-31

2014

Link zum Volltext

Verfügbarkeit prüfen

Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

Annals of oncology, 2017-12, Vol.28, p.xi31-xi31

2017

Link zum Volltext

Verfügbarkeit prüfen

IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

Annals of oncology, 2017-04, Vol.28, p.ii50

2017

Link zum Volltext

Verfügbarkeit prüfen

IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC

Annals of oncology, 2017-04, Vol.28, p.ii19

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

Annals of oncology, 2016-10, Vol.27, p.vi493-vi493

2016

Link zum Volltext

Verfügbarkeit prüfen

480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)

Annals of oncology, 2016-12, Vol.27, p.ix154-ix154

2016

Link zum Volltext

Verfügbarkeit prüfen

521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Link zum Volltext

Verfügbarkeit prüfen

521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)

Annals of oncology, 2016-12, Vol.27, p.ix169-ix169

2016

Link zum Volltext

Verfügbarkeit prüfen

480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Link zum Volltext

Verfügbarkeit prüfen

355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC

Annals of oncology, 2015-12, Vol.26, p.ix103-ix103

2015

Link zum Volltext

Verfügbarkeit prüfen

A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)

Annals of oncology, 2016-10, Vol.27, p.vi496-vi496

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3090-3090

2011

Link zum Volltext

Verfügbarkeit prüfen

The Evaluation of Selumetinib a MEK-Inhibitor with and without the Addition of Erlotinib in KRAS Mutated Non-Small Cell Lung Cancer

Annals of oncology, 2013-03, Vol.24, p.i7-i7

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of thymic epithelial tumors (TETs) at the National Cancer Institute (NCI)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e17511-e17511

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e17525-e17525

2010

Link zum Volltext

Verfügbarkeit prüfen

The Hydrostatic and Hydrodynamic Volumes of Polyols in Aqueous Solutions and Their Sweet Taste

Chemical senses, 1997-04, Vol.22 (2), p.149-161

1997

Link zum Volltext

Verfügbarkeit prüfen

Laparoscopic Approach by Hemi-Hysterectomy in Patient With Herlyn-Werner-Wünderlich Syndrome

Journal of minimally invasive gynecology, 2015-11, Vol.22 (6), p.S133-S133

2015

Link zum Volltext

Verfügbarkeit prüfen

Muehrcke lines associated to active rheumatoid arthritis

Journal of clinical rheumatology, 2013-01, Vol.19 (1), p.30

2013

Link zum Volltext

Verfügbarkeit prüfen

Solution properties and tastes of sugar alcohols

Food quality and preference, 1993, Vol.4 (1), p.105-106

1993

Link zum Volltext

Verfügbarkeit prüfen

Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis

Allergologia et immunopathologia, 2005, Vol.33 (5), p.291-292

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 442

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(328)
Mit Volltextzugriff
(392)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Scorpion sting envenomation outbreak in Mexico. Strategies for prevention and control

Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Treatment Receipt and Outcomes among Lung Cancer Patients with Depression

Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

IMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)

521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)

521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)

480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)

355TiP Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC

A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)

A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors

The Evaluation of Selumetinib a MEK-Inhibitor with and without the Addition of Erlotinib in KRAS Mutated Non-Small Cell Lung Cancer

Management of thymic epithelial tumors (TETs) at the National Cancer Institute (NCI)

Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC)

The Hydrostatic and Hydrodynamic Volumes of Polyols in Aqueous Solutions and Their Sweet Taste

Laparoscopic Approach by Hemi-Hysterectomy in Patient With Herlyn-Werner-Wünderlich Syndrome

Muehrcke lines associated to active rheumatoid arthritis

Solution properties and tastes of sugar alcohols

Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis

Suchergebnisse filtern